Talking about the scoping study and recovery rates.
The importance of high recovery rates using HPAL cannot be overstated. The NPV due to capital cost is going to be a bummer in my view but if analysts see the recovery rates affording healthy feed stock then we get a big tick as @roblun has suggested numerous times.
Also if the NPV and IRR are not great the analysts should factor in the the other 50% of Mt Thirsty that GAL has.
I don't put much weight on the scandium and it is not included in this study anyway so the capital cost should not factor in a scandium circuit.
Talking about the scoping study and recovery rates.The...
Add GSR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
-0.001(10.0%) |
Mkt cap ! $12.35M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $38.32K | 4.277M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 3234381 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 298045 | 1 |
View Market Depth
| Last trade - 15.31pm 30/04/2024 (20 minute delay) ? |
| GSR (ASX) Chart |